Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials

摘要: Summary Linezolid has been approved for the treatment of patients with infections caused by Gram-positive cocci that are resistant to traditionally used antibiotics, including glycopeptides. This oxazolidinone antibiotic reported have excellent pharmacokinetics and effectiveness. We did a meta-analysis randomised controlled trials (RCTs) clarify whether linezolid is superior glycopeptides or β-lactams infections. 12 RCTs, involving 6093 patients, were included. Overall, respect success, was more effective than (odds ratio [OR] 1·41 [95% CI 1·11–1·81]). Mortality similar between groups (OR 0·97 [0·79–1·19]). comparators in skin soft-tissue 1·67 [1·31–2·12]) bacteraemia 2·07 [1·13–3·78]). However, there no difference success pneumonia 1·03 [0·75–1·42]). Treatment not associated adverse effects general 1·40 [0·95–2·06]); however, thrombocytopenia recorded commonly receiving 11·72 [3·66–37·57]). Although its empirical selected several points, such as use less potent antistaphylococcal β-lactams, same all-cause mortality, higher probability thrombocytopenia, should be taken into account may limit specific patient populations difficult treat other antibiotics.